TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11232677

Group type: COMPARATOR
Intervention: Nasogastric administration of SOS (40 mg dose)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Jejunal/duodenal administration of SOS (40 mg dose)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All routes of administration (nasogastric, jejunal, duodenal)
Number of subjects: 9
Study: 9490600

Group type: EXPERIMENTAL
Intervention: Thyroxine suppressive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative thyroxine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monitoring without thyroxine treatment
Number of subjects: 0
Study: 7817355

Group type: EXPERIMENTAL
Intervention: 2 mg trandolapril once daily for 30 days (D21 to D50)
Number of subjects: 23
Study: 29625762

Group type: EXPERIMENTAL
Intervention: PCT and antidepressants
Number of subjects: 289

Group type: COMPARATOR
Intervention: Antidepressants alone
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: PCT with tapering of antidepressants
Number of subjects: 289
Study: 26220763

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium lactis, Bifidobacterium longum, or a combination of both)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Probiotics (Bifidobacterium supplements)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Probiotics and Placebo
Number of subjects: 199
Study: 24983746

Group type: EXPERIMENTAL
Intervention: Semagacestat (100 mg and 140 mg)
Number of subjects: 1537

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1537
Study: 23726675

Group type: EXPERIMENTAL
Intervention: Naloxegol 25mg
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Naloxegol 50mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 19892338

Group type: EXPERIMENTAL
Intervention: Metformin therapy (group 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling (group 2)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 110
Study: 18370880

Group type: EXPERIMENTAL
Intervention: Latanoprost treatment
Number of subjects: 22
Study: 16822992

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (ECF regimen: epirubicin 50 mg/m², cisplatin 60 mg/m², fluorouracil 200 mg/m²/day for 21 days) and surgery
Number of subjects: 503

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (ECF regimen)
Number of subjects: 503
Study: 14572521

Group type: EXPERIMENTAL
Intervention: High frequency rTMS over left DLPFC
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline without stimulation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High frequency rTMS over right DLPFC
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High frequency rTMS over right cerebellum
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low frequency rTMS over left DLPFC
Number of subjects: 16
Study: 10742350

Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Conditioning alarm
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 8956299

Group type: EXPERIMENTAL
Intervention: Nifedipine infusion from isolation of aorta until end of surgery (group A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-dose dopamine infusion over the same surgical course (group B)
Number of subjects: 16
Study: 1286501

Group type: EXPERIMENTAL
Intervention: Flumazenil (maximum dose of 1 mg, administered intravenously at 0.2 mg at 1-minute intervals)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo (10 ml administered at 1-minute intervals)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 3927551

Group type: EXPERIMENTAL
Intervention: Leuprolide (1 mg per day, subcutaneous injection)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES) (3 mg per day, oral)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Leuprolide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Diethylstilbestrol (DES)
Number of subjects: 21
Study: 31266016

Group type: EXPERIMENTAL
Intervention: Tango argentino
Number of subjects: 29

Group type: COMPARATOR
Intervention: Tai Chi
Number of subjects: 29
Study: 29588062

Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity aerobic exercise
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy controls (n = 35)
Number of subjects: 68
Study: 27189180

Group type: EXPERIMENTAL
Intervention: e-learning EDUCAGUIA (educational games with hypothetical clinical scenarios in a virtual environment)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Usual dissemination strategy by e-mail (Control group)
Number of subjects: 394
Study: 23695648

Group type: EXPERIMENTAL
Intervention: Exercise training (30 min of moderate-intensity treadmill exercise, followed by resistance and stretching exercises, performed three times a week for 6 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 30
Study: 22646631

Group type: EXPERIMENTAL
Intervention: Whole-body cooling to an esophageal temperature of 33.5°C for 72 hours, followed by slow rewarming
Number of subjects: 208

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Whole-body cooling
Number of subjects: 208
Study: 20798395

Group type: EXPERIMENTAL
Intervention: Non-invasive testing (NIT) for sexually transmitted infections (STI)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Standard of care (SOC) STI testing with genital examination
Number of subjects: 391
Study: 18850394

Group type: EXPERIMENTAL
Intervention: Risk-focused imagery
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Recommendation-focused imagery
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Ease of imagery (mediator)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control (no imagery)
Number of subjects: 314
Study: 15607841

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 1175
Study: 12120779

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (self-etching primer system)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single Bond (single-bottle adhesive system with total-etch wet bonding technique)
Number of subjects: 0
Study: 10453373

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (maximum dose 22 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 64
Study: 7598065

Group type: EXPERIMENTAL
Intervention: Low-protein diet (1.47 g protein.kg body cell mass‐1.d‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adequate-protein diet (2.94 g protein.kg body cell mass‐1.d‐1)
Number of subjects: 0
Study: 2087856

Group type: EXPERIMENTAL
Intervention: Interval training (20:121 watts, rest:work 1:1 min)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Continuous training (83 watts)
Number of subjects: 18
Study: 388295

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31823206

Group type: EXPERIMENTAL
Intervention: Topical Low Dose Preservative-Free Hydrocortisone
Number of subjects: 0
Study: 30640654

Group type: EXPERIMENTAL
Intervention: Epidurally applied levobupivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intravenously applied morphine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 70
Study: 27653753

Group type: EXPERIMENTAL
Intervention: Caregiver-training programme with telephone consultation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Written educational materials and social telephone follow-ups (Control)
Number of subjects: 116
Study: 25880004

Group type: COMPARATOR
Intervention: S-1
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: SOX
Number of subjects: 271
Study: 24306438

Group type: EXPERIMENTAL
Intervention: Observation of a video of an actor performing in a CW environment
Number of subjects: 3

Group type: COMPARATOR
Intervention: Physical practice only group
Number of subjects: 3
Study: 22954642

Group type: EXPERIMENTAL
Intervention: PURPLE materials (DVD and booklet)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Analogous control materials on infant safety
Number of subjects: 201
Study: 19683639

Group type: EXPERIMENTAL
Intervention: Percutaneous closure of the left atrial appendage (LAA) and subsequent discontinuation of warfarin (n=463)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Warfarin treatment with a target international normalised ratio between 2.0 and 3.0 (n=244)
Number of subjects: 707

Group type: EXPERIMENTAL
Intervention: Percutaneous closure of the left atrial appendage (LAA)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Warfarin treatment
Number of subjects: 707
Study: 17295727

Group type: EXPERIMENTAL
Intervention: Confidence in ability to change (single-item measure)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Intention to abstain (single-item measure)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Single-item measures of readiness, importance, and intention to cut down
Number of subjects: 312
Study: 16320926

Group type: EXPERIMENTAL
Intervention: L-arginine (7.5 g in 500 ml of cardioplegic solution)
Number of subjects: 28
Study: 11910365

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with adequate generation of the allocation sequence
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials with adequate allocation concealment
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Randomized clinical trials that were double blind
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Methodological quality improvement in trials
Number of subjects: 383
Study: 9791527

Group type: EXPERIMENTAL
Intervention: 20-minute video intervention to increase safety awareness
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (comparison group parents)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 20-minute video intervention
Number of subjects: 80
Study: 7714648

Group type: EXPERIMENTAL
Intervention: Pneumatic sequential leg compression devices (PSLCDs)
Number of subjects: 304

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 304
Study: 2522110

Group type: EXPERIMENTAL
Intervention: Sulpiride treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lithium treatment
Number of subjects: 8
Study: 493897

Group type: EXPERIMENTAL
Intervention: Independent exercises
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 42
Study: 31982695

Group type: EXPERIMENTAL
Intervention: Neutrophil chemotaxis activity in survivors
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Combination of neutrophil chemotaxis activity with mHLA-DR, CD-11b expression, presepsin, and SOFA score
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Decreased neutrophil chemotaxis activity
Number of subjects: 136
Study: 29886470

Group type: EXPERIMENTAL
Intervention: ORS III
Number of subjects: 76

Group type: COMPARATOR
Intervention: ORS I
Number of subjects: 76
Study: 25425655

Group type: EXPERIMENTAL
Intervention: Budesonide (mean dose 4.5 mg/day; Budenofalk 3 mg capsules, two or one capsule on alternate days)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 92
Study: 24885593

Group type: EXPERIMENTAL
Intervention: Individual Work Performance Questionnaire (IWPQ)
Number of subjects: 260
Study: 22237275

Group type: EXPERIMENTAL
Intervention: Cervical fixed-point traction manipulation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cervical computer traction
Number of subjects: 84
Study: 20346113

Group type: COMPARATOR
Intervention: Clothed manikin (three layers)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Undressed manikin
Number of subjects: 48
Study: 18366264

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 832
Study: 15845879

Group type: EXPERIMENTAL
Intervention: Water deprivation for 24 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal water intake
Number of subjects: 16
Study: 12428824

Group type: EXPERIMENTAL
Intervention: TENS (60 minutes, 5 days a week for 4 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo stimulation (60 minutes, 5 days a week for 4 weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Isometric exercise training (5 days a week for 4 weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: TENS & Exercise (5 days a week for 4 weeks)
Number of subjects: 62
Study: 10959785

Group type: EXPERIMENTAL
Intervention: Coronal Scaling (CS)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Subgingival Scaling (SS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Coronal Scaling (CS) and Subgingival Scaling (SS)
Number of subjects: 39
Study: 8776122

Group type: EXPERIMENTAL
Intervention: Intradermal pins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Synthetic braided absorbable suture (Control)
Number of subjects: 0
Study: 2060255

Group type: EXPERIMENTAL
Intervention: 2% MK-927 (1.2 mg) q.i.d.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.8% sezolamide (1.1 mg) q.i.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Common vehicle q.i.d.
Number of subjects: 16
Study: 6403135

Group type: EXPERIMENTAL
Intervention: Oral glucose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous glucose
Number of subjects: 8
Study: 31124272

Group type: EXPERIMENTAL
Intervention: rFVIIa (100 ± 20 μg/kg dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Emicizumab prophylaxis
Number of subjects: 0
Study: 29756595

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF) 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 0
Study: 27139057

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (54 Gy plus capecitabine)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Chemotherapy (1000 mg/m2 weekly of gemcitabine)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Gemcitabine plus erlotinib (100 mg/d)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Gemcitabine alone
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 449
Study: 26017589

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment (45 mg) applied to mastectomy skin at the time of surgical dressing
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo applied to mastectomy skin at the time of surgical dressing
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 22236639

Group type: EXPERIMENTAL
Intervention: Myofascial release (MFR)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sham ultrasound therapy (Control)
Number of subjects: 68
Study: 20068494

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg x kg(-1) body mass)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine (various doses)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Time of day (evening vs morning)
Number of subjects: 9
Study: 18719863

Group type: EXPERIMENTAL
Intervention: Endoscopic retrograde cholangiography (ERC) with or without endoscopic sphincterotomy (ES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Open bile duct surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic removal of CBDS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endosonography or magnetic resonance cholangiopancreatography
Number of subjects: 0
Study: 15831804

Group type: EXPERIMENTAL
Intervention: Measured resting metabolic rate (RMR) using indirect calorimetry and energy cost of walking at 5.6 km/h in a subsample of 49 men and 49 women.
Number of subjects: 769

Group type: EXPERIMENTAL
Intervention: Using measured or predicted RMR as a correction factor for estimating energy cost of walking.
Number of subjects: 769
Study: 11838628

Group type: COMPARATOR
Intervention: Sertraline treatment (50 to 200 mg/day) during the acute phase
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Continuation treatment with sertraline
Number of subjects: 359

Group type: COMPARATOR
Intervention: Discontinuation of sertraline (double-blind)
Number of subjects: 359
Study: 10416848

Group type: EXPERIMENTAL
Intervention: Symbol prompting correct lifting posture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 7677455

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) + Glutamine (GLN) + Diet (DIET)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Long-term therapy with GH + GLN + DIET
Number of subjects: 47
Study: 2119392

Group type: EXPERIMENTAL
Intervention: 0.5 mg leuprolide acetate (GnRH agonist)
Number of subjects: 14

Group type: COMPARATOR
Intervention: 5000 IU hCG
Number of subjects: 14
Study: 6195025

Group type: EXPERIMENTAL
Intervention: Intradermally injected bleomycin in saline and oil
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 31959226

Group type: EXPERIMENTAL
Intervention: Auricular point acupressure (APA) group (active points related to cLBP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group-1 (non-active points, unrelated to cLBP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group-2 (enhanced educational control, an educational booklet on cLBP)
Number of subjects: 0
Study: 31263231

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - received exploration feedback during the Test phase.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (CG) - did not receive exploration feedback during the Test phase.
Number of subjects: 0
Study: 28625282

Group type: EXPERIMENTAL
Intervention: High-intensity exercise program (treadmill running, >70% to 85% of maximal oxygen consumption, 3 times a week for 24 weeks)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Non-exercise control group
Number of subjects: 433
Study: 27484017

Group type: EXPERIMENTAL
Intervention: Oralair® (8200 BAU)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Grazax® (6200 BAU)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Staloral® (12000 BAU/ml)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Soluprick® (10300 BAU/ml)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Reference extract (10000 BAU/ml)
Number of subjects: 33
Study: 23957902

Group type: EXPERIMENTAL
Intervention: Positive self-image intervention
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Implementation intention intervention
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Standard intention condition
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Interrogative intention condition
Number of subjects: 7000

Group type: EXPERIMENTAL
Intervention: Regret plus intention condition
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 7000
Study: 22669134

Group type: EXPERIMENTAL
Intervention: Abdominal and pelvic floor muscle retraining (including diaphragmatic breathing exercises)
Number of subjects: 43
Study: 18495456

Group type: EXPERIMENTAL
Intervention: Dietary treatment with varying total choline (344-486 mg/day), betaine (122-349 mg/day) and/or folate (400-800 microg dietary folate equivalents/day) for 12 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MTHFR C677T genotype
Number of subjects: 45
Study: 20943715

Group type: EXPERIMENTAL
Intervention: Visual locomotor imagery training
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Kinesthetic locomotor imagery training with auditory step rhythm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Kinesthetic locomotor imagery training
Number of subjects: 15
Study: 15921475

Group type: EXPERIMENTAL
Intervention: Active implementation strategy (2 sessions with education, group discussion, role playing, feedback, and reminders)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard passive method of dissemination (guidelines by mail)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Active implementation strategy
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard passive method of dissemination
Number of subjects: 500
Study: 11883349

Group type: EXPERIMENTAL
Intervention: 10‐mg PGE2 vaginal insert
Number of subjects: 200

Group type: COMPARATOR
Intervention: 3‐mg PGE2 tablets (administered twice at six‐hour intervals)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 3‐mg PGE2 tablets
Number of subjects: 200
Study: 10084465

Group type: EXPERIMENTAL
Intervention: Salbutamol (1,200 microg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 7737632

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (URSO)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 2115444

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg(24 h)‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (mean dose: 40 +/‐ 9 micrograms min‐1)
Number of subjects: 16
Study: 7355391

Group type: EXPERIMENTAL
Intervention: Cimetadine (three preoperative doses)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Glycopyrrolate (0.005 mg/kg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Atropine (0.01 mg/kg)
Number of subjects: 84
Study: 31711605

Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 2 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 4 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 8 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: saline
Number of subjects: 18
Study: 30567598

Group type: EXPERIMENTAL
Intervention: Active music-instruction intervention
Number of subjects: 68
Study: 26921136

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone, 200 mg daily from 22-24 to 34 weeks of gestation
Number of subjects: 1228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1228
Study: 24052092

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (10-week intervention)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 76